Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

被引：0
|
作者：
Kim, Jaemin [1 ]
Lee, Youngjoo [1 ,2 ,3 ]
机构：
[1] Natl Canc Ctr, Res Inst, Goyang, South Korea
[2] Natl Canc Ctr, Dept Internal Med, Div Hematol & Oncol, Goyang, South Korea
[3] Natl Canc Ctr, Dept Internal Med, Div Hematol & Oncol, 323 Ilsan Ro, Goyang 10408, South Korea
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2023年 / 4卷 / 12期
关键词：
NSCLC; EGFR exon 20 insertion; Drug resistance; Anti-angiogenesis; Targeted therapy; Case report; GROWTH;
D O I：
10.1016/j.jtocrr.2023.100600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was successfully treated by combining therapy of another EGFR exon 20 insertion-specific targeted drug mobocertinib and bevacizumab.(c) 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
    Zhang, Shannon S.
    Zhu, Viola W.
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 61 - 65
  • [22] Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
    Gonzalvez, Francois
    Vincent, Sylvie
    Baker, Theresa E.
    Gould, Alexandra E.
    Li, Shuai
    Wardwell, Scott D.
    Nadworny, Sara
    Ning, Yaoyu
    Zhang, Sen
    Huang, Wei-Sheng
    Hu, Yongbo
    Li, Feng
    Greenfield, Matthew T.
    Zech, Stephan G.
    Das, Biplab
    Narasimhan, Narayana, I
    Clackson, Tim
    Dalgarno, David
    Shakespeare, William C.
    Fitzgerald, Michael
    Chouitar, Johara
    Griffin, Robert J.
    Liu, Shengwu
    Wong, Kwok-Kin
    Zhu, Xiaotian
    Rivera, Victor M.
    [J]. CANCER DISCOVERY, 2021, 11 (07) : 1672 - 1687
  • [23] Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
    Seo, Donghyun
    Lim, Jun Hyeok
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [24] FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Chon, Katie
    Larkins, Erin
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Aungst, Stephanie
    Wearne, Emily
    Subramaniam, Sriram
    Li, Yangbing
    Liu, Jiang
    Sun, Jielin
    Charlab, Rosane
    Zhao, Hong
    Saritas-Yildirim, Banu
    Bikkavilli, Rama Kamesh
    Ghosh, Soma
    Philip, Reena
    Beaver, Julia A.
    Singh, Harpreet
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3262 - 3266
  • [25] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
    Choi, Dae-Ho
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong -Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
  • [26] Bispecific Approach for Patients with non-small cell Lung Cancer Benefiting from Amivantamab for EGFR-Exon-20-Insertion Mutations
    Rudesheim, Sabine M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 214 - 214
  • [27] Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
    Mok, T. S. K.
    Liu, G.
    Nyaw, S. F.
    Curcio, H.
    Cortot, A.
    Kam, T. Y.
    Descourt, R.
    Chik, Y. K.
    Cheema, P. K.
    Gwinnutt, J. M.
    Churchill, E. N.
    Nyborn, J.
    Curran, E.
    Yin, Y.
    Chong, K.
    Tanaka-Chambers, Y.
    Kretz, J.
    Cadranel, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1698 - S1699
  • [28] Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma A case report
    Inagaki, Yuji
    Tamiya, Akihiro
    Matsuda, Yoshinobu
    Azuma, Kouji
    Adachi, Yuichi
    Enomoto, Takatoshi
    Kouno, Shunichi
    Taniguchi, Yoshihiko
    Saijo, Nobuhiko
    Okishio, Kyoichi
    Atagi, Shinji
    [J]. MEDICINE, 2020, 99 (42)
  • [29] Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
    Pacini, Laura
    Jenks, Andrew D.
    Vyse, Simon
    Wilding, Christopher P.
    Arthur, Amani
    Huang, Paul H.
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 301 - 317
  • [30] A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
    Choi, D.
    Jung, H. A.
    Park, S.
    Sun, J-M.
    Ahn, J. S.
    Ahn, M-J.
    Lee, S-H.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1696 - S1696
12345